PBYI · Puma Biotechnology, Inc. · Webcasts, Transcripts & Audio
$8.25
-1.52 (-15.56%)
At close · Nov 6
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$404.44M
Shares
51.62M
Volume · Nov 6
1.28M
Avg daily vol (3M)
353.77K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Puma Biotechnology, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Puma Biotechnology, Inc. (PBYI), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-05
Puma Biotechnology, Inc. (PBYI) Q3 2026 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-14
Puma Biotechnology, Inc. (PBYI) September 14, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-09
Puma Biotechnology, Inc. (PBYI) September 9, 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-06
Puma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call Transcript
Positive tone
Breast cancer unmet need and marketing
Financial discipline and positive net income
Trial dosing and protocol amendments
Revenue
$56.50M
▲ 7.8% YoY Diluted EPS
$0.16
▲ 33.3% YoY Gross margin
77.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-07
Puma Biotechnology, Inc. (PBYI) Q1 2026 Earnings Call Transcript
Positive tone
Alisca Lung-1 Phase II trial
Unmet medical need / company mission
Dose escalation
Revenue
$44.81M
▼ 2.6% YoY Diluted EPS
$-0.07
▼ 216.7% YoY Gross margin
76.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Puma Biotechnology, Inc. (PBYI) Q4 2025 Earnings Call Transcript
Positive tone
NERLYNX Commercial Performance
ALISCA-Lung1 Trial
ALISCA-Breast1 Trial
Revenue
$75.45M*
▲ 27.7% YoY Gross margin
69.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Puma Biotechnology, Inc. (PBYI) Q3 2025 Earnings Call Transcript
Positive tone
NERLYNX commercial performance
Alisertib ALISCA-Breast1 trial
Regulatory and development path for alisertib
Revenue
$54.48M
▼ 32.4% YoY Diluted EPS
$0.17
▼ 58.5% YoY Gross margin
77.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Puma Biotechnology, Inc. (PBYI) Q2 2025 Earnings Call Transcript
Positive tone
ALISCA-Breast Phase II trial
NERLYNX commercial performance
ALISCA-Lung1 Phase II trial
Revenue
$52.44M
▲ 11.4% YoY Diluted EPS
$0.12
Gross margin
76.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Puma Biotechnology, Inc. (PBYI) Q1 2025 Earnings Call Transcript
Positive tone
NERLYNX commercial performance
Alisertib clinical development
Neratinib combination data with Enhertu
Revenue
$46.01M
▲ 5.1% YoY Diluted EPS
$0.06
Gross margin
77.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Puma Biotechnology, Inc. (PBYI) Q4 2024 Earnings Call
Revenue
$59.08M*
▼ 18.2% YoY Gross margin
76.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Puma Biotechnology, Inc. (PBYI) Q3 2024 Earnings Call Transcript
Positive tone
Alisertib safety / tolerability profile
Royalty revenue from China/Pierre Fabre
NERLYNX commercial performance
Revenue
$80.54M
▲ 43.5% YoY Diluted EPS
$0.41
▲ 241.7% YoY Gross margin
63.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Puma Biotechnology, Inc. (PBYI) Q2 2024 Earnings Call Transcript
Positive tone
Alisertib clinical development
NERLYNX commercial performance
Royalty revenue and China dynamics
Revenue
$47.08M
▼ 13.7% YoY Diluted EPS
$-0.09
▼ 280% YoY Gross margin
77.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Puma Biotechnology, Inc. (PBYI) Q1 2024 Earnings Call Transcript
Balanced tone
Alisertib clinical pipeline
NERLYNX product revenue decline
Sales force and HCP engagement
Revenue
$43.77M
▼ 17.1% YoY Diluted EPS
$-0.10
▼ 433.3% YoY Gross margin
75.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-29
Puma Biotechnology, Inc. (PBYI) Q4 2023 Earnings Call Transcript
Positive tone
Alisertib Pipeline Development
NERLYNX Commercial Performance
Business Development and In-Licensing
Revenue
$72.18M*
▲ 9.9% YoY Gross margin
66.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Puma Biotechnology, Inc. (PBYI) Q3 2023 Earnings Call Transcript
Revenue
$56.12M
▼ 1.7% YoY Diluted EPS
$0.12
Gross margin
76.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Puma Biotechnology, Inc. (PBYI) Q2 2023 Earnings Call Transcript
Revenue
$54.57M
▼ 8.3% YoY Diluted EPS
$0.05
▼ 76.2% YoY Gross margin
78.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Puma Biotechnology, Inc. (PBYI) Q1 2023 Earnings Call Transcript
Revenue
$52.77M
▲ 15.4% YoY Diluted EPS
$0.03
Gross margin
75.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-02
Puma Biotechnology, Inc. (PBYI) Q4 2022 Earnings Call Transcript
Revenue
$65.67M*
▲ 18.6% YoY Gross margin
74.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Puma Biotechnology, Inc. (PBYI) Q3 2022 Earnings Call Transcript
Revenue
$57.10M
▲ 23.5% YoY Diluted EPS
$-0.01
Gross margin
78.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Puma Biotechnology, Inc. (PBYI) Q2 2022 Earnings Call Transcript
Revenue
$59.52M
▲ 11.5% YoY Diluted EPS
$0.21
Gross margin
74.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Puma Biotechnology, Inc. (PBYI) Q1 2022 Earnings Call Transcript
Revenue
$45.74M
▼ 53.4% YoY Diluted EPS
$-0.08
▼ 120% YoY Gross margin
76.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-03
Puma Biotechnology, Inc. (PBYI) Q4 2021 Earnings Call Transcript
Revenue
$55.36M*
▲ 5.3% YoY Gross margin
78.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Puma Biotechnology, Inc. (PBYI) Q3 2021 Earnings Call Transcript
Revenue
$46.24M
▼ 8.9% YoY Diluted EPS
$-1.09
Gross margin
77.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Puma Biotechnology, Inc. (PBYI) Q2 2021 Earnings Call Transcript
Revenue
$53.38M
▼ 24.4% YoY Diluted EPS
$-0.13
▼ 262.5% YoY Gross margin
77.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Puma Biotechnology, Inc. (PBYI) Q1 2021 Earnings Call Transcript
Revenue
$98.17M
▲ 91.7% YoY Diluted EPS
$0.40
Gross margin
69.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
Puma Biotechnology, Inc. (PBYI) Q4 2020 Earnings Call Transcript
Revenue
$52.56M
▼ 16.5% YoY Diluted EPS
$-0.38
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Puma Biotechnology, Inc. (PBYI) Q3 2020 Earnings Call Transcript
Revenue
$50.75M
▼ 9.9% YoY Diluted EPS
$-0.79
Gross margin
80.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Puma Biotechnology, Inc. (PBYI) Q2 2020 Earnings Call Transcript
Revenue
$70.58M
▲ 30.9% YoY Diluted EPS
$0.08
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Puma Biotechnology, Inc. (PBYI) Q1 2020 Earnings Call Transcript
Revenue
$51.22M
▼ 48.3% YoY Diluted EPS
$-0.43
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-20
Puma Biotechnology, Inc. (PBYI) Q4 2019 Earnings Call
Revenue
$62.92M
▼ 11.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–30 of 30 webcasts
Key facts
CIK
1401667
CUSIP
74587V107
13F (30d)
60 filings
48 filers
Visit website
Investor relations